Company intelligence / Profile preview
Suzhou Zerun New Drug Development
Suzhou, Jiangsu, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Suzhou Zerun New Drug Development is a Chinese biotechnology company focused on the research and development of innovative small molecule therapeutics, particularly for infectious diseases. The company's primary focus is the development of advanced treatments for chronic hepatitis B (HBV), aiming to provide more effective options for the large patient population in China and globally. Its lead candidate, ZB-001, is a prodrug of tenofovir designed to improve safety and efficacy profiles compared to existing treatments. Suzhou Zerun operates within the Suzhou Industrial Park, leveraging the region's robust biotech ecosystem to advance its clinical pipeline.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Suzhou Zerun New Drug Development.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Suzhou Zerun New Drug Development.